0001708138-22-000020.txt : 20220318 0001708138-22-000020.hdr.sgml : 20220318 20220318160521 ACCESSION NUMBER: 0001708138-22-000020 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220316 FILED AS OF DATE: 20220318 DATE AS OF CHANGE: 20220318 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tessier-Lavigne Marc CENTRAL INDEX KEY: 0001437435 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 22752508 MAIL ADDRESS: STREET 1: 1 DNA WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2022-03-16 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001437435 Tessier-Lavigne Marc 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 1 0 0 0 Common Stock 2022-03-16 4 M 0 4361 374.12 A 6630 D Common Stock 2022-03-16 4 S 0 4361 675.0 D 2269 D Common Stock 2022-03-17 4 M 0 7830 376.69 A 10099 D Common Stock 2022-03-17 4 S 0 7830 680.0 D 2269 D Non-Qualified Stock Option (right to buy) 374.12 2022-03-16 4 M 0 4361 0.0 D 2030-01-02 Common Stock 4361 0 D Non-Qualified Stock Option (right to buy) 376.69 2022-03-17 4 M 0 7830 0.0 D 2027-01-03 Common Stock 7830 0 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. /s/**Marc Tessier-Lavigne 2022-03-18